Galapagos NV (WBO:GLPG) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Galapagos NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Galapagos NV's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.00.

Galapagos NV's long-term debt to total assets ratio increased from Mar. 2024 (0.00) to Mar. 2025 (0.00). It may suggest that Galapagos NV is progressively becoming more dependent on debt to grow their business.

Galapagos NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for Galapagos NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV LT-Debt-to-Total-Asset Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Galapagos NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Galapagos NV LT-Debt-to-Total-Asset Calculation

Galapagos NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	8.243	/	4135.719
	=	0.00

Galapagos NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )	/	Total Assets (Q: Mar. 2025 )
	=	7.787	/	4021.946
	=	0.00

Galapagos NV (WBO:GLPG) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Galapagos NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Galapagos NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (WBO:GLPG) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXEA:Germany GXE:Germany GXEA:Germany GXE:Germany G1LP34:Brazil

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.